Literature DB >> 16061962

Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-infected individuals.

Janet D Siliciano1, Robert F Siliciano.   

Abstract

Highly active antiretroviral therapy can decrease plasma HIV-1 levels to below the limit of detection. However, HIV-1 persists in latently infected resting-memory CD4+ T-cells carrying an integrated copy of the viral genome. The pool of latently infected cells is extremely stable and represents a major barrier to HIV-1 eradication. Identification and characterization of this reservoir required the development of methods for purifying resting CD4+ T-cells from HIV-1-infected individuals, activating the cells to induce virus production, and detecting and quantitating cells capable of releasing infectious virus. The development of an enhanced viral culture assay to quantitate the number of latently infected cells carrying replication competent virus is described here.

Entities:  

Mesh:

Year:  2005        PMID: 16061962     DOI: 10.1385/1-59259-907-9:003

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  165 in total

1.  HIV-1 DNA is detected in bone marrow populations containing CD4+ T cells but is not found in purified CD34+ hematopoietic progenitor cells in most patients on antiretroviral therapy.

Authors:  Christine M Durand; Gabriel Ghiaur; Janet D Siliciano; S Alireza Rabi; Evelyn E Eisele; Maria Salgado; Liang Shan; Jun F Lai; Hao Zhang; Joseph Margolick; Richard J Jones; Joel E Gallant; Richard F Ambinder; Robert F Siliciano
Journal:  J Infect Dis       Date:  2012-01-24       Impact factor: 5.226

Review 2.  Measuring the latent reservoir in vivo.

Authors:  Marta Massanella; Douglas D Richman
Journal:  J Clin Invest       Date:  2016-02-01       Impact factor: 14.808

Review 3.  HIV reservoirs and latency models.

Authors:  Matthew J Pace; Luis Agosto; Erin H Graf; Una O'Doherty
Journal:  Virology       Date:  2011-02-01       Impact factor: 3.616

Review 4.  The Alphabet Soup of HIV Reservoir Markers.

Authors:  Radwa R Sharaf; Jonathan Z Li
Journal:  Curr HIV/AIDS Rep       Date:  2017-04       Impact factor: 5.071

5.  Patients on HAART often have an excess of unintegrated HIV DNA: implications for monitoring reservoirs.

Authors:  Luis M Agosto; Megan K Liszewski; Angela Mexas; Erin Graf; Matthew Pace; Jianqing J Yu; Avinash Bhandoola; Una O'Doherty
Journal:  Virology       Date:  2011-01-05       Impact factor: 3.616

Review 6.  HIV-1 transcription and latency: an update.

Authors:  Carine Van Lint; Sophie Bouchat; Alessandro Marcello
Journal:  Retrovirology       Date:  2013-06-26       Impact factor: 4.602

7.  Short-Term Pegylated Interferon α2a Treatment Does Not Significantly Reduce the Viral Reservoir of Simian Immunodeficiency Virus-Infected, Antiretroviral Therapy-Treated Rhesus Macaques.

Authors:  David Palesch; Steven E Bosinger; Maud Mavigner; James M Billingsley; Cameron Mattingly; Diane G Carnathan; Mirko Paiardini; Ann Chahroudi; Thomas H Vanderford; Guido Silvestri
Journal:  J Virol       Date:  2018-06-29       Impact factor: 5.103

8.  A humanized mouse-based HIV-1 viral outgrowth assay with higher sensitivity than in vitro qVOA in detecting latently infected cells from individuals on ART with undetectable viral loads.

Authors:  Paige Charlins; Kimberly Schmitt; Leila Remling-Mulder; Louise E Hogan; Emily Hanhauser; Kristen S Hobbs; Frederick Hecht; Steven G Deeks; Timothy J Henrich; Ramesh Akkina
Journal:  Virology       Date:  2017-04-19       Impact factor: 3.616

9.  No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy.

Authors:  Rajesh T Gandhi; Ronald J Bosch; Evgenia Aga; Mary Albrecht; Lisa M Demeter; Carrie Dykes; Barbara Bastow; Michael Para; Jun Lai; Robert F Siliciano; Janet D Siliciano; Joseph J Eron
Journal:  J Infect Dis       Date:  2010-01-15       Impact factor: 5.226

10.  Identification of ongoing human immunodeficiency virus type 1 (HIV-1) replication in residual viremia during recombinant HIV-1 poxvirus immunizations in patients with clinically undetectable viral loads on durable suppressive highly active antiretroviral therapy.

Authors:  Carlum Shiu; Coleen K Cunningham; Thomas Greenough; Petronella Muresan; Victor Sanchez-Merino; Vincent Carey; J Brooks Jackson; Carrie Ziemniak; Lawrence Fox; Marvin Belzer; Stuart C Ray; Katherine Luzuriaga; Deborah Persaud
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.